TY - JOUR
T1 - The diagnostic significance of CDH17-positive circulating tumor cells in patients with colorectal cancer
AU - Pei, Xiao Meng
AU - Wong, Heong Ting
AU - Ng, Simon Siu Man
AU - Leung, Wing Wa
AU - Wong, Yee Ni
AU - Tsang, Hin Fung
AU - Chan, Amanda Kit Ching
AU - Wong, Yin Kwan Evelyn
AU - Yu, Allen Chi Shing
AU - Yim, Aldrin Kay Yuen
AU - Cho, William Chi Shing
AU - Chan, John Kwok Cheung
AU - Wong, Kwong Fai
AU - Luk, John M.
AU - Tai, William Chi Shing
AU - Wong, Sze Chuen Cesar
N1 - Funding Information:
The authors would like to thank the Research Grants Council HK (RGC-Q71P) and HK Innovation and Technology Fund University-Industry Collaborative Programme (ITC/UIM354) for financial supports of this study.
Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023/2
Y1 - 2023/2
N2 - Background: Colorectal cancer (CRC) is the second leading cause of cancer deaths in Hong Kong. We tested the hypothesis that circulating tumor cell (CTC) analysis by ARB101 antibody could be used as a tool for CRC detection, progression, and therapy response. Research Methods: ARB101 antibody was used for investigation of CDH17 expression in formalin-fixed, paraffin-embedded (FFPE) tissue sections and circulating tumor cells (CTCs) of CRC patients. Results: Using ARB101, highest sensitivity was observed in 98/100 (98%) colorectal cancer tissue compared to 72/100 gastric cancer (72%) and 27/32 pancreatic cancer (84%). Immunoreactivity of CDH17 was significantly higher in distant metastatic (tumor-node-metastasis [TNM] stage IV) than non-distant metastatic (TNM stage I to III) CRC. ARB101 antibody also manifested the higher sensitivity than c-erbB2 (8%) and epidermal growth factor receptor (EGFR)-targeting antibodies (37%) with the significance (p < 0.0001). ARB101 positive CTCs were detected in 64/83 (77%) TNM stage I to IV CRC patients. Furthermore, ARB101 positive CTCs detected in TNM stage I to III CRC patients before and after surgical operation are statistically significant (p < 0.0001). Conclusions: CTC detection by ARB101 antibody could serve as a potential non-invasive approach for CRC detection, progression, and monitoring of treatment response.
AB - Background: Colorectal cancer (CRC) is the second leading cause of cancer deaths in Hong Kong. We tested the hypothesis that circulating tumor cell (CTC) analysis by ARB101 antibody could be used as a tool for CRC detection, progression, and therapy response. Research Methods: ARB101 antibody was used for investigation of CDH17 expression in formalin-fixed, paraffin-embedded (FFPE) tissue sections and circulating tumor cells (CTCs) of CRC patients. Results: Using ARB101, highest sensitivity was observed in 98/100 (98%) colorectal cancer tissue compared to 72/100 gastric cancer (72%) and 27/32 pancreatic cancer (84%). Immunoreactivity of CDH17 was significantly higher in distant metastatic (tumor-node-metastasis [TNM] stage IV) than non-distant metastatic (TNM stage I to III) CRC. ARB101 antibody also manifested the higher sensitivity than c-erbB2 (8%) and epidermal growth factor receptor (EGFR)-targeting antibodies (37%) with the significance (p < 0.0001). ARB101 positive CTCs were detected in 64/83 (77%) TNM stage I to IV CRC patients. Furthermore, ARB101 positive CTCs detected in TNM stage I to III CRC patients before and after surgical operation are statistically significant (p < 0.0001). Conclusions: CTC detection by ARB101 antibody could serve as a potential non-invasive approach for CRC detection, progression, and monitoring of treatment response.
KW - ARB101
KW - CDH17
KW - circulating tumor cells
KW - Colorectal cancer
UR - http://www.scopus.com/inward/record.url?scp=85147775258&partnerID=8YFLogxK
U2 - 10.1080/14737159.2023.2176223
DO - 10.1080/14737159.2023.2176223
M3 - Journal article
C2 - 36744385
AN - SCOPUS:85147775258
SN - 1473-7159
VL - 23
SP - 171
EP - 179
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
IS - 2
ER -